HER2-Positive Breast Cancer | Topics

 
Supplemental New Drug Application Submitted in Japan for Trastuzumab Deruxtecan in HER2-Low Breast Cancer
July 05, 2022

Patients with HER2-low unresectable or recurrent breast cancer in Japan could receive treatment with trastuzumab deruxtecan in the future if the newly submitted supplemental new drug application for this indication is approved.

European Medicines Agency Recommends T-DXd for Approval in European Union in Advanced HER2+ Breast Cancer
June 29, 2022

The Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended for approval trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive breast cancer.

De-Escalation Trastuzumab/Pertuzumab ± Paclitaxel Yields Promising Responses in HER2+/HR– Early Breast Cancer
June 21, 2022

Results from the WSG-ADAPT-HER2+/HR- study showed promising survival rates with pathological complete response when patients with HER2-positive, hormone receptor-negative early breast cancer were treated with a de-escalated dose of trastuzumab plus pertuzumab without or without paclitaxel over a 12-week period.

Tucatinib To Be Examined as Add-On to First-Line Maintenance in HER2+ Metastatic Breast Cancer
June 08, 2022

The phase 3 HER2CLIMB-05 trial will investigate tucatinib plus standard of care maintenance in the first-line setting for patients with HER2-positive metastatic breast cancer.

Trastuzumab Deruxtecan Use for Metastatic HER2+ Breast Cancer Validated at Safety Analysis
June 04, 2022

An acceptable safety reported at a follow-up analysis of the phase 3 DESTINY-Breast03 study has reinforced use of fam-trastuzumab deruxtecan-nxki for patients with HER2-positive unresectable or metastatic breast cancer

De-escalated Trastuzumab Plus Pertuzumab Regimen May Be Feasible for Subsets of HER2+, HR– Early Breast Cancer
June 01, 2022

A de-escalated regimen of trastuzumab and pertuzumab without added paclitaxel may be an option for certain patients with HER2-positive, hormone receptor–negative early-stage breast cancer.

Sara Hurvitz, MD, Spoke on Efficacy of T-DXd in HER2+ Breast Cancer With Brain Metastases
June 01, 2022

Sara Hurvitz, MD, spoke about ongoing clinical trials in which trastuzumab deruxtecan is being investigated with the use of brain metastases.

Sara Hurvitz, MD, on the Benefit of Second-Line T-DXd in Subgroups of HER2+ Breast Cancer
May 30, 2022

Sara Hurvitz, MD, spoke which patients would benefit most from fam-trastuzumab deruxtecan and what the next research steps will be.

Sara Hurvitz, MD, Speaks to Improvements in Treatment for HER2+ Breast Cancer
May 29, 2022

Sara Hurvitz, MD, spoke to the difficulty of treating HER2-positive and advanced HER2-positive breast cancer and how the efficacy of novel agents such as fam-trastuzumab deruxtecan-nxki could make a difference in treating the disease.

Sara Hurvitz, MD, Discusses the Full Approval of Second-Line T-DXd in HER2+ Breast Cancer
May 26, 2022

Sara Hurvitz, MD, spoke about to recent approval of fam-trastuzumab deruxtecan-nxki in the second-line setting for patients with HER2-positive breast cancer.